文献速递间质性肺疾病肺结节与肺癌

免疫检查点抑制剂对合并间质性肺疾病的非小细胞肺癌患者生存获益的全国性人群研究

Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study.
PubMed 文献 · Thorax · 2026-03-13

基于日本全国保险理赔数据库,比较接受ICIs(n=1748)与仅化疗(n=6362)的ILD-NSCLC患者,ICIs组中位OS显著更长(19.7 vs 9.9个月,HR 0.51,95%CI 0.47-0.54,p<0.001),虽药物性ILD发生率更高,但合并DIILD与否OS无显著差异;倾向性匹配后一线ICIs组OS仍显著优于匹配化疗组。

要点

  • 合并ILD的NSCLC患者使用ICIs中位OS 19.7个月,显著优于单纯化疗的9.9个月。
  • ICIs组药物性ILD发生率显著高于化疗组,但发生DIILD者与未发生者OS无显著差异。
  • 倾向性匹配后一线ICIs组OS仍显著优于匹配化疗组。

核心结论

  • 在ILD-NSCLC患者中,ICIs相比细胞毒性化疗与显著更长的OS相关,尽管DIILD风险增加。

研究设计与样本

  • 基于日本全国保险理赔数据库的回顾性队列研究,ICIs组n=1748,化疗组n=6362,并进行倾向性评分匹配比较一线ICIs组与匹配化疗组各753例。

主要发现

  • ICIs组中位OS为19.7个月,化疗组为9.9个月(HR 0.51,95%CI 0.47-0.54,p<0.001)。
  • 在3、6、9和12个月的landmark分析中,ICIs组OS均显著长于化疗组(均p<0.001)。
  • ICIs组药物性ILD发生率显著高于化疗组(p<0.001)。
  • ICIs组中,发生与未发生DIILD的患者OS无显著差异(p=0.784)。
  • 倾向性评分匹配分析显示,一线ICIs组OS显著长于匹配化疗组(p<0.001)。

临床怎么用

  • 对于合并ILD的NSCLC患者,ICIs可作为较化疗更优的生存选择,但需警惕药物性ILD风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Compared with cytotoxic chemotherapy, the efficacy and safety of immune checkpoint inhibitors (ICIs) for patients with interstitial lung disease and non-small cell lung cancer (ILD-NSCLC) are unclear. METHODS: Data of patients in a Japanese nationwide insurance claims database with ILD-NSCLC who received ICIs (ICI group, n=1748) and those who received only chemotherapy without ICIs (chemotherapy group, n=6362) were extracted. Landmark analyses were performed to compare overall survival (OS) between the two groups. Propensity-score matching was performed to compare 753 patients who received ICI as the first-line treatment (first-ICI group) and 753 from the chemotherapy group with matched backgrounds (matched chemotherapy group). RESULTS: The ICI group had a significantly longer median OS of 19.7 months than the chemotherapy group (9.9 months; HR 0.51, 95% CI 0.47 to 0.54, p<0.001). In landmark analyses at 3, 6, 9 and 12 months, the ICI group had a significantly longer OS than the chemotherapy group (all p<0.001). The incidence of drug-induced ILD (DIILD) was significantly higher in the ICI group than in the chemotherapy group (p<0.001). In the ICI group, there was no significant difference in OS between patients with and without DIILD (p=0.784). A propensity score-matched analysis indicated that the first-ICI group had a significantly longer OS than the matched chemotherapy group (p<0.001). CONCLUSIONS: In patients with ILD-NSCLC, ICIs were associated with significantly longer OS compared with cytotoxic chemotherapy, despite the increased risk of DIILD.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Karayama M, Miyashita K, Inoue Y, et al. Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study. Thorax. 2026. PMID: 41093568. doi:10.1136/thorax-2025-223430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。